Please assess the completion status of the following clinical trial:

Trial Title: Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of CM according to ICHD-3 criteria for at least 12 months prior to enrollment;~* completion of a full headache diary in the 3 months preceding the enrollment; compliance to complete a daily headache diary for 1 year;~* previous failure of at least 3 classes of preventive treatments among beta-blockers, antiepileptic drugs, antidepressants, or onabotulinumtoxin-A;~* MIDAS score \> 11.~Exclusion Criteria:~* severe cardiologic comorbidities;~* pregnancy and breastfeeding;~* previous adverse reaction to latex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).